search
Back to results

Sleep Apnea in Sickle Cell Disease (DREPAPNEE)

Primary Purpose

Sickle Cell Disease

Status
Terminated
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
polysomnography and oxygen saturation exam
calculation of VOC frequency between the first polysomnography and the end of the first year of continuous positive airway pressure treatment
Blood samples
Physiological measurements
Continuous Positive Airway Pressure
Sponsored by
Hospices Civils de Lyon
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Sickle Cell Disease focused on measuring sickle cell disease, obstructive sleep apnoea, vaso-occlusive crisis

Eligibility Criteria

15 Years - 50 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Homozygous HbS (Hemoglobin S) (SS) patients,
  • aged between 15 and 3 months and 50 years old,
  • in steady state (i.e. without vaso-occlusive crisis or recent blood transfusion),
  • followed by the sickle cell center of the Hospices Civils de Lyon,
  • and showing symptoms of OSA.

Exclusion Criteria:

  • Patients receiving treatment of OSA,
  • recent blood transfusion (less than 2 months),
  • patients not at steady state (VOC or acute chest syndrome less than 2 months),
  • pregnancy.

Sites / Locations

  • Hôpital Edouard Herriot
  • Centre Léon Berard
  • Hôpital de la Croix Rousse

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

SS patients

SS patients apneic

Arm Description

Homozygous sickle cell patients Each patient will undergo the following: polysomnography and oxygen saturation exam calculation of VOC rate within the two previous years Blood samples Physiological measurements

Homozygous sickle cell patients after one year of continuous positive airway pressure treatment Each patient will undergo the following: polysomnography and oxygen saturation exam calculation of VOC rate within the two previous years Blood samples Physiological measurements

Outcomes

Primary Outcome Measures

number of VOC crises required hospitalization in the previous two years
Calculated over a 2 years period before inclusion. VOC requiring hospitalizations will be recorded. Measured at day 1

Secondary Outcome Measures

Blood inflammatory markers
Blood inflammatory markers : C Reactive Protein (CRP, mg/L) The morning after the polysomnography blood samples will be collected (M1 +/- 15 days)
Blood inflammatory markers
Blood inflammatory markers : C Reactive Protein (CRP, mg/L)
Markers of blood coagulation
Biological risk factors of VOC : prothrombin time (PT, s), D-dimer (µg/L), Fibrinogen (g/L), Activated Thromboplastin Time (APPT, s), protein C and protein S (%) The morning after the polysomnography blood samples will be collected (M1 +/- 15 days)
Markers of blood coagulation
prothrombin time (PT, s), D-dimer (µg/L), Fibrinogen (g/L), Activated Thromboplastin Time (APPT, s), protein C and protein S (%)
Blood cell counts and markers of hemolysis
Biological risk factors of VOC : Blood cell counts and markers of hemolysis : red blood cell count (G/L), neutrophil count (G/L), hemoglobin concentration (g/dL), hematocrit (%), mean corpuscular volume (MCV, fl), mean corpuscular hemoglobin concentration (MCHC, pg), platelet count (G/L), lactate dehydrogenase (LDH, IU), bilirubin (µg/L), aspartate transaminase (AST, U/L). The morning after the polysomnography blood samples will be collected (M1 +/- 15 days)
Blood cell counts and markers of hemolysis
Blood cell counts and markers of hemolysis : red blood cell count (G/L), neutrophil count (G/L), hemoglobin concentration (g/dL), hematocrit (%), mean corpuscular volume (MCV, fl), mean corpuscular hemoglobin concentration (MCHC, pg), platelet count (G/L), lactate dehydrogenase (LDH, IU), bilirubin (µg/L), aspartate transaminase (AST, U/L).
Markers of nitric oxide metabolism
Biological risk factors of VOC : markers of nitric oxide production nitrites, nitrate, nitrotyrosine The morning after the polysomnography blood samples will be collected (M1 +/- 15 days)
Markers of nitric oxide metabolism
markers of nitric oxide production nitrites, nitrate, nitrotyrosine
Oxidative stress markers
Biological risk factors of VOC : protein oxidation marker (advanced oxidation protein products), markers of lipid peroxidation (malondialdehyde), antioxidant enzymatic activities (super oxide dismutase, catalase, glutathione peroxidase), antioxidant power (ferric reducing ability of plasma) The morning after the polysomnography blood samples will be collected (M1 +/- 15 days)
Oxidative stress markers
protein oxidation marker (advanced oxidation protein products), markers of lipid peroxidation (malondialdehyde), antioxidant enzymatic activities (super oxide dismutase, catalase, glutathione peroxidase), antioxidant power (ferric reducing ability of plasma)
Hemorheological parameters
blood viscosity (cP) measured with a cone plate viscometer at several shear rates, red blood cell deformability (a.u) measured by ektacytometry at several shear stresses, red blood cell aggregation (%) properties measured by laser backscatter method. The morning after the polysomnography blood samples will be collected (M1 +/- 15 days)
Hemorheological parameters
Biological risk factors of VOC : blood viscosity (cP) measured with a cone plate viscometer at several shear rates, red blood cell deformability (a.u) measured by ektacytometry at several shear stresses, red blood cell aggregation (%) properties measured by laser backscatter method.
Arterial blood gases
Biological risk factors of VOC : oxygen and carbon dioxide pressure (mmHg), pH The morning after the polysomnography blood samples will be collected (M1 +/- 15 days)
Arterial blood gases
oxygen and carbon dioxide pressure (mmHg), pH
Vascular function (microvascular reactivity to skin heating test)
Physiological risk factors of VOC : A laser Doppler flowmeter (Periflux 5000 Perimed) will be used to measure skin blood flow in resting condition and during a local thermal hyperemia (LTH) test (temperature will be increased from 33 °C to 42 °C) for 35 min. The peak response during the LTH reflects vasodilatation caused by axonal reflex while the delayed plateau response of the LTH test is mainly dependent on the ability to produce nitric oxide to promote vasodilation.
Vascular function (microvascular reactivity to skin heating test)
A laser Doppler flowmeter (Periflux 5000 Perimed) will be used to measure skin blood flow in resting condition and during a local thermal hyperemia (LTH) test (temperature will be increased from 33 °C to 42 °C) for 35 min. The peak response during the LTH reflects vasodilatation caused by axonal reflex while the delayed plateau response of the LTH test is mainly dependent on the ability to produce nitric oxide to promote vasodilation.
autonomic nervous system activity (measured by heart rate variability analysis)
Physiological risk factors of VOC : electrocardiographic signals acquired by the polysomnographic machine will be extracted and the R-R intervals will be used for time domain spectral analyses to calculate several indices reflecting the activity of the autonomic nervous system activity. The ratio between the low frequency and the high frequency powers (LF/HF) will be used to characterize the autonomic imbalance.
autonomic nervous system activity (measured by heart rate variability analysis)
electrocardiographic signals acquired by the polysomnographic machine will be extracted and the R-R intervals will be used for time domain spectral analyses to calculate several indices reflecting the activity of the autonomic nervous system activity. The ratio between the low frequency and the high frequency powers (LF/HF) will be used to characterize the autonomic imbalance.
Frequency of VOC
Number of VOC requiring hospitalizations during the past year

Full Information

First Posted
November 20, 2018
Last Updated
December 23, 2022
Sponsor
Hospices Civils de Lyon
search

1. Study Identification

Unique Protocol Identification Number
NCT03753854
Brief Title
Sleep Apnea in Sickle Cell Disease
Acronym
DREPAPNEE
Official Title
Effects of Obstructive Sleep Apnea on the Frequency of Vaso-occlusive Crises Events and Bio-physical Markers in Sickle Cell Disease
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Terminated
Why Stopped
Recruitment difficulties
Study Start Date
May 28, 2018 (Actual)
Primary Completion Date
November 29, 2021 (Actual)
Study Completion Date
November 29, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospices Civils de Lyon

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Despite the fact that obstructive sleep apnoea (OSA) is highly prevalent in the sickle cell population, studies focusing on the associations of the two diseases and their common pathophysiological mechanisms are scarce. OSA is one of the most common conditions responsible for hemoglobin desaturation. The nocturnal hemoglobin desaturation occurring in some sickle cell disease (SCD) patients with OSA could trigger hemoglobin S polymerization and red blood cell (RBC) sickling, leading to further blood rheological alterations, hence increasing the risks for VOC. Moreover, OSA has been demonstrated to increase oxidative stress and inflammation in non Sickle Cell Disease (SCD) patients, which, in SCD patients, could increase the risk for complications. Finally, OSA is accompanied by impaired vascular function and autonomic nervous system dysfunction in the general population. Indeed, the presence of OSA in SCD could increase the clinical severity of patients and the frequency of VOC.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sickle Cell Disease
Keywords
sickle cell disease, obstructive sleep apnoea, vaso-occlusive crisis

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SS patients
Arm Type
Active Comparator
Arm Description
Homozygous sickle cell patients Each patient will undergo the following: polysomnography and oxygen saturation exam calculation of VOC rate within the two previous years Blood samples Physiological measurements
Arm Title
SS patients apneic
Arm Type
Experimental
Arm Description
Homozygous sickle cell patients after one year of continuous positive airway pressure treatment Each patient will undergo the following: polysomnography and oxygen saturation exam calculation of VOC rate within the two previous years Blood samples Physiological measurements
Intervention Type
Diagnostic Test
Intervention Name(s)
polysomnography and oxygen saturation exam
Intervention Description
Measurement of the Apnea/hypopnea index (AHI) and oxygen saturation
Intervention Type
Biological
Intervention Name(s)
calculation of VOC frequency between the first polysomnography and the end of the first year of continuous positive airway pressure treatment
Intervention Description
calculation of VOC rate within the two previous years or between first polysomnography and one year of continuous positive airway pressure treatment
Intervention Type
Biological
Intervention Name(s)
Blood samples
Intervention Description
Blood samples with measurements of hematological, hemorheological, inflammatory and blood coagulation markers
Intervention Type
Other
Intervention Name(s)
Physiological measurements
Intervention Description
Evaluation of microvascular reactivity and autonomic nervous system activity
Intervention Type
Other
Intervention Name(s)
Continuous Positive Airway Pressure
Intervention Description
Continuous Positive Airway Pressure during 1 year
Primary Outcome Measure Information:
Title
number of VOC crises required hospitalization in the previous two years
Description
Calculated over a 2 years period before inclusion. VOC requiring hospitalizations will be recorded. Measured at day 1
Time Frame
day 1
Secondary Outcome Measure Information:
Title
Blood inflammatory markers
Description
Blood inflammatory markers : C Reactive Protein (CRP, mg/L) The morning after the polysomnography blood samples will be collected (M1 +/- 15 days)
Time Frame
An average of 1 month
Title
Blood inflammatory markers
Description
Blood inflammatory markers : C Reactive Protein (CRP, mg/L)
Time Frame
Day 365
Title
Markers of blood coagulation
Description
Biological risk factors of VOC : prothrombin time (PT, s), D-dimer (µg/L), Fibrinogen (g/L), Activated Thromboplastin Time (APPT, s), protein C and protein S (%) The morning after the polysomnography blood samples will be collected (M1 +/- 15 days)
Time Frame
An average of 1 month
Title
Markers of blood coagulation
Description
prothrombin time (PT, s), D-dimer (µg/L), Fibrinogen (g/L), Activated Thromboplastin Time (APPT, s), protein C and protein S (%)
Time Frame
Day 365
Title
Blood cell counts and markers of hemolysis
Description
Biological risk factors of VOC : Blood cell counts and markers of hemolysis : red blood cell count (G/L), neutrophil count (G/L), hemoglobin concentration (g/dL), hematocrit (%), mean corpuscular volume (MCV, fl), mean corpuscular hemoglobin concentration (MCHC, pg), platelet count (G/L), lactate dehydrogenase (LDH, IU), bilirubin (µg/L), aspartate transaminase (AST, U/L). The morning after the polysomnography blood samples will be collected (M1 +/- 15 days)
Time Frame
An average of 1 month
Title
Blood cell counts and markers of hemolysis
Description
Blood cell counts and markers of hemolysis : red blood cell count (G/L), neutrophil count (G/L), hemoglobin concentration (g/dL), hematocrit (%), mean corpuscular volume (MCV, fl), mean corpuscular hemoglobin concentration (MCHC, pg), platelet count (G/L), lactate dehydrogenase (LDH, IU), bilirubin (µg/L), aspartate transaminase (AST, U/L).
Time Frame
Day 365
Title
Markers of nitric oxide metabolism
Description
Biological risk factors of VOC : markers of nitric oxide production nitrites, nitrate, nitrotyrosine The morning after the polysomnography blood samples will be collected (M1 +/- 15 days)
Time Frame
An average of 1 month
Title
Markers of nitric oxide metabolism
Description
markers of nitric oxide production nitrites, nitrate, nitrotyrosine
Time Frame
Day 365
Title
Oxidative stress markers
Description
Biological risk factors of VOC : protein oxidation marker (advanced oxidation protein products), markers of lipid peroxidation (malondialdehyde), antioxidant enzymatic activities (super oxide dismutase, catalase, glutathione peroxidase), antioxidant power (ferric reducing ability of plasma) The morning after the polysomnography blood samples will be collected (M1 +/- 15 days)
Time Frame
An average of 1 month
Title
Oxidative stress markers
Description
protein oxidation marker (advanced oxidation protein products), markers of lipid peroxidation (malondialdehyde), antioxidant enzymatic activities (super oxide dismutase, catalase, glutathione peroxidase), antioxidant power (ferric reducing ability of plasma)
Time Frame
Day 365
Title
Hemorheological parameters
Description
blood viscosity (cP) measured with a cone plate viscometer at several shear rates, red blood cell deformability (a.u) measured by ektacytometry at several shear stresses, red blood cell aggregation (%) properties measured by laser backscatter method. The morning after the polysomnography blood samples will be collected (M1 +/- 15 days)
Time Frame
An average of 1 month
Title
Hemorheological parameters
Description
Biological risk factors of VOC : blood viscosity (cP) measured with a cone plate viscometer at several shear rates, red blood cell deformability (a.u) measured by ektacytometry at several shear stresses, red blood cell aggregation (%) properties measured by laser backscatter method.
Time Frame
Day 365
Title
Arterial blood gases
Description
Biological risk factors of VOC : oxygen and carbon dioxide pressure (mmHg), pH The morning after the polysomnography blood samples will be collected (M1 +/- 15 days)
Time Frame
An average of 1 month
Title
Arterial blood gases
Description
oxygen and carbon dioxide pressure (mmHg), pH
Time Frame
Day 365
Title
Vascular function (microvascular reactivity to skin heating test)
Description
Physiological risk factors of VOC : A laser Doppler flowmeter (Periflux 5000 Perimed) will be used to measure skin blood flow in resting condition and during a local thermal hyperemia (LTH) test (temperature will be increased from 33 °C to 42 °C) for 35 min. The peak response during the LTH reflects vasodilatation caused by axonal reflex while the delayed plateau response of the LTH test is mainly dependent on the ability to produce nitric oxide to promote vasodilation.
Time Frame
Day 1
Title
Vascular function (microvascular reactivity to skin heating test)
Description
A laser Doppler flowmeter (Periflux 5000 Perimed) will be used to measure skin blood flow in resting condition and during a local thermal hyperemia (LTH) test (temperature will be increased from 33 °C to 42 °C) for 35 min. The peak response during the LTH reflects vasodilatation caused by axonal reflex while the delayed plateau response of the LTH test is mainly dependent on the ability to produce nitric oxide to promote vasodilation.
Time Frame
Day 365
Title
autonomic nervous system activity (measured by heart rate variability analysis)
Description
Physiological risk factors of VOC : electrocardiographic signals acquired by the polysomnographic machine will be extracted and the R-R intervals will be used for time domain spectral analyses to calculate several indices reflecting the activity of the autonomic nervous system activity. The ratio between the low frequency and the high frequency powers (LF/HF) will be used to characterize the autonomic imbalance.
Time Frame
Day 1
Title
autonomic nervous system activity (measured by heart rate variability analysis)
Description
electrocardiographic signals acquired by the polysomnographic machine will be extracted and the R-R intervals will be used for time domain spectral analyses to calculate several indices reflecting the activity of the autonomic nervous system activity. The ratio between the low frequency and the high frequency powers (LF/HF) will be used to characterize the autonomic imbalance.
Time Frame
Day 365
Title
Frequency of VOC
Description
Number of VOC requiring hospitalizations during the past year
Time Frame
Day 365

10. Eligibility

Sex
All
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Homozygous HbS (Hemoglobin S) (SS) patients, aged between 15 and 3 months and 50 years old, in steady state (i.e. without vaso-occlusive crisis or recent blood transfusion), followed by the sickle cell center of the Hospices Civils de Lyon, and showing symptoms of OSA. Exclusion Criteria: Patients receiving treatment of OSA, recent blood transfusion (less than 2 months), patients not at steady state (VOC or acute chest syndrome less than 2 months), pregnancy.
Facility Information:
Facility Name
Hôpital Edouard Herriot
City
Lyon
ZIP/Postal Code
69003
Country
France
Facility Name
Centre Léon Berard
City
Lyon
ZIP/Postal Code
69008
Country
France
Facility Name
Hôpital de la Croix Rousse
City
Lyon
ZIP/Postal Code
69317
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
34630163
Citation
Stauffer E, Poutrel S, Cannas G, Gauthier A, Fort R, Bertrand Y, Renoux C, Joly P, Boisson C, Hot A, Peter-Derex L, Pialoux V, PetitJean T, Connes P. Nocturnal Hypoxemia Rather Than Obstructive Sleep Apnea Is Associated With Decreased Red Blood Cell Deformability and Enhanced Hemolysis in Patients With Sickle Cell Disease. Front Physiol. 2021 Sep 24;12:743399. doi: 10.3389/fphys.2021.743399. eCollection 2021.
Results Reference
derived

Learn more about this trial

Sleep Apnea in Sickle Cell Disease

We'll reach out to this number within 24 hrs